Trilogy Capital Inc. Reduces Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Trilogy Capital Inc. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,307 shares of the biopharmaceutical company’s stock after selling 3,765 shares during the quarter. Trilogy Capital Inc.’s holdings in Gilead Sciences were worth $3,446,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in GILD. FMR LLC raised its stake in shares of Gilead Sciences by 79.4% in the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after purchasing an additional 14,680,161 shares in the last quarter. Wellington Management Group LLP raised its stake in Gilead Sciences by 50.9% during the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after buying an additional 11,665,593 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in Gilead Sciences by 723.3% during the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock worth $594,370,000 after buying an additional 5,653,075 shares during the last quarter. Point72 Asset Management L.P. grew its position in shares of Gilead Sciences by 350.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock worth $193,274,000 after acquiring an additional 1,793,145 shares in the last quarter. Finally, International Assets Investment Management LLC increased its holdings in shares of Gilead Sciences by 8,238.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock valued at $137,708,000 after acquiring an additional 1,622,806 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 1.7 %

Shares of NASDAQ:GILD opened at $99.65 on Thursday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $100.51. The firm has a fifty day moving average of $92.71 and a two-hundred day moving average of $86.32. The firm has a market capitalization of $124.19 billion, a P/E ratio of 1,107.22, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the business earned $2.29 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post 4.34 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 142,180 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at $12,626,253.06. The trade was a 52.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 572,824 shares of company stock worth $53,611,715. Insiders own 0.29% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of several research analyst reports. The Goldman Sachs Group raised their price objective on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Morgan Stanley raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $87.00 to $113.00 in a report on Friday, January 10th. Sanford C. Bernstein assumed coverage on Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price for the company. Finally, Piper Sandler raised their price target on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.